Thursday, March 28, 2019 3:28:16 PM
During the Roth conference Q&A, when asked about the value of the platform, Mark mentioned two comparisons:
Glycophy bought by Merck for $420MM in 2007
Protein Sciences (Baculovirus platform) bought by Sanofi Pasteur for $650MM
It's clear they believe C1 to be vastly superior to either of these, and are engaging with as many pharma's as possible to advance specific programs, and increase visibility and value. And with their cash on-hand they're in absolutely no rush to sell
Listen to the webcast from the 24:30 mark to get a sense of the market opportunity and the platform's value and Mark's confidence.
Market cap today: $85MM
Recent DYAI News
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
